Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018801 (heart failure)
 72,216 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The case of surgical treatment of a 44-years old female with a double atrio-ventricular accessory pathway and mitral stenosis was described. Fast ventricular rates due to conduction through the accessory pathways during atrial fibrillation in course of mitral stenosis caused severe heart failure, occasionally with deep hypotonia. Combined treatment with prajmaline and propafenone blocked conduction through accessory pathways. The ventricular rate slowed from approx. 200/min to 150/min. Addition of digoxin slowed the ventricular rate down to approx 80-100/min. There were no signs of preexcitation. Treatment with diuretics and vasodilators was continued. The state of patient improved. Echocardiographic and hemodynamic evaluation revealed: mitral stenosis (orifice - 75 mm2) with moderate regurgitation, small aortic and tricuspid regurgitation. The coronary arteries were normal. On the base of the ECG recordings during atrial fibrillation both accessory pathways were localized on lateral and posterior parts of the left free wall. The patient was operated on. Both atrio-ventricular by-pass tracts were dissected using Sealy's method in Cox modification and then mitral valve prosthesis Medtronic-Hall 27 mm was implanted. Prajmaline and propafenone were discontinued and preexcitation did not recovered. The sinus rhythm was restored by electroversion. The patient had no overt heart failure on discharge from the Institute.
Kardiol Pol 1990 Jan
PMID:[Dissection of the accessory conduction pathways with simultaneous mitral valve surgery]. 227 77

In 61 patients with class IV (NYHA) of chronic congestive cardiac failure treated for 2 weeks with digoxin (0.290 +/- 0.108 mg/d) and furosemide (13.0 +/- 4.1 mg/d), for 2 weeks with digoxin, furosemide and isosorbide dinitrate (44.5 +/- 9.8 mg/d) or nifedipine (42.0 +/- 12.2 mg/d), for 4 weeks with digoxin, furosemide, isosorbide or nifedipine and captopril (angiotensin converting enzyme inhibitor) (75.1 +/- 24.4 mg/d), and for the last 2 weeks with digoxin, furosemide, isosorbide or nifedipine without captopril, after each stage the clinical state, exercise tolerance and haemodynamic parameters determined echocardiographically were assessed. Ten weeks of treatment by this method caused regression of pulmonary congestion in 80%, oedema in 63.3% and hepatomegaly in 33.3% of the patients. Moreover, 60.7% of the patients returned to class III, 13.1% to class II, and 26.2% remained in class IV (NYHA). In the group treated with digoxin, furosemide, nifedipine with captopril (n = 30) a significant rise was observed of the value of the ejection fraction and cardiac index in relation to the treatment with digoxin and furosemide and the treatment with digoxin, furosemide, nifedipine (p less than 0.05). No drug improved significantly the tolerance of submaximal exercise. During the treatment with captopril no clinical improvement was achieved in 4 cases, and worsening occurred in 3 cases of severe cardiac failure (7 of 61 patients, 11.5%). The obtained results showed that vasodilating drugs are safe in congestive cardiac failure and in many cases of severe failure captopril contributed to rapid clinical and haemodynamic improvement.
Pol Arch Med Wewn 1990 Aug
PMID:[Results of treatment for severe congestive heart failure with digoxin, furosemide and vasodilating agents]. 227 87

Lymphocyte beta-adrenergic receptor density and plasma catecholamine concentrations were determined in 28 patients with acute myocardial infarction and compared with those in patients with angina pectoris and healthy persons. In patients with acute myocardial infarction beta-adrenergic receptor density was significantly lower (p less than 0.001) and plasma catecholamine levels significantly higher (p less than 0.001) as compared with corresponding values in patients with angina pectoris or healthy persons. beta-adrenergic receptor density in patients with angina pectoris were not significantly different from those in controls. A significant negative correlation between beta-adrenergic receptor density and plasma norepinephrine levels was observed in patients with acute myocardial infarction (r = -0.593; p less than 0.001; r = -0.615; p less than 0.001 respectively). It is suggested that decreased beta-adrenergic receptor density is a consequence of elevated plasma catecholamine levels in patients with acute myocardial infarction. It has been well documented that acute myocardial infarction is associated with enhanced activity of the sympathetic nervous system. Several studies have already been done showing that urinary excretion of catecholamines and plasma catecholamine concentrations are raised in the acute phase of myocardial infarction. Particularly high levels of plasma catecholamines appeared to be related to the severity of clinical course of myocardial infarction and were found in patients with cardiogenic shock, heart failure and arrhythmias. It is of interest that the peak elevation of plasma catecholamines correlated with the extent of myocardial damage as reflected by peak plasma CK activity and also correlated with acute and long-term mortality.(ABSTRACT TRUNCATED AT 250 WORDS)
Mater Med Pol
PMID:Beta-adrenergic receptors and catecholamines in acute myocardial infarction. 256 61

Authors presented the organization of Mobile Intensive Cardiological Care Unit (MICCU) and discussed its interventions during the first year of activity. In 1987 the total number of interventions was 3333 (mean 9 per day), including 150 in acute myocardial infarction, 142 in acute rhythm or conduction disorders, 56 in acute heart failure and 36 in cardiac arrest. Efficacy of MICCV work recommended the the circulatory system.
Kardiol Pol 1989
PMID:[Mobile Intensive Cardiological Care Unit. 12-month experience]. 261 37

24 endomyocardial biopsies were performed in children aged 4-18 (x = 12.9) without any complications. The endomyocardial biopsy was performed in 12 patients with the heart failure of unknown origin (6 - restrictive heart disease, 4 - dilated cardiomyopathy with arrhythmias, 2-post-inflammatory dilated cardiomyopathy), in 5 patients with a clinical diagnosis of myocarditis, in 1 with the hypertrophic cardiomyopathy, in 2 cases of the dilated cardiomyopathy without heart failure and in 1 girl with the recurrent exudative pericarditis. Active myocarditis with fibrosis was stated in 2 cases of a restrictive heart disease, mild inflammatory state in 2 patients with a clinical diagnosis of the myocarditis and in 3 others with the dilated cardiomyopathy. All of 7 patients with the myocarditis underwent the immunosuppressive therapy. In the patient with endomyocardial fibrosis the result of left ventricular biopsy corresponded with angiocardiographic diagnosis. Non-specific changes in biopsies were stated in 2 children with the restrictive cardiomyopathy and in 5 with the dilated cardiomyopathy. Bioptic, morphologic lesions in patients with the dilated cardiomyopathy did not correlate with hemodynamic parameters of contractility. Biopsies were normal in 6 subjects. Endomyocardial biopsy influenced on making a decision of the therapy in 9 of 21 patients (42.8%). Diagnosis was verified in 7 patients (38.3%) basing on endomyocardial biopsy. In 18 of 24 subjects (75%) endomyocardial biopsy contributed to the interpretation of the disease pathology.
Kardiol Pol 1989
PMID:[Endomyocardial biopsy in children and adolescents]. 261 40

Late results of 6-month immunosuppressive therapy (prednisone from 1.5 mg/kg b.w. and azathioprine 2 mg/kg b.w.) simultaneously performed with a conventional treatment were analyzed in 20 patients with heart failure of unknown origin and bioptic diagnosed myocarditis. Average patients' age was 33.8 +/- 10.7 years, mean disease duration--7.8 month, mean left ventricular ejection fraction--25.9 +/- 8.9%. Follow up period was at least 24 months in all patients. 1 patient died before the end of therapy. After 6-month immunosuppressive therapy improvement was stated in 10 patients (50%)--group A, stable disease course in 3 (15%)--group B and deterioration in remaining 6 (30%)--group C. After the next 18 month conventional therapy as many as in 8 of 10 group A patients deterioration was observed, further improvement (EF increase from 17% to 43%) in 1 female patient and a stable disease course in the another female. Of 3 group B patients in 1 further improvement was observed and a stable course in 2 remaining. Of 6 group C patients 4 died, 1 underwent cardiac transplantation, 1 female patient is still alive, but does not put herself to control examinations. Early improvement after 6-month immunosuppressive treatment does not prejudge the later prognosis.
Kardiol Pol 1989
PMID:[Late results of immunosuppressive therapy in patients with heart failure and biopsy proven myocarditis]. 263 19

Authors performed comparative measurements of cardiac output using the impedance rheography and Fick's method in healthy men (6) reaching the value of correlation coefficient 0.88 and in patients with acquired cardiac defects (n = 21; r = 0.68). Authors also compared cardiac output values measured at rest and during exercise by means of thermodilution and rheographic methods in patients with heart failure (n = 9). Correlation coefficient was respectively 0.92 and 0.81.
Kardiol Pol 1989
PMID:[Comparative investigation of cardiac output using impedance rheography and invasive methods]. 263 22

Therapeutic effectiveness of lidocaine intravenous infusions preceded by an initial intravenous dose was studied in 29 patients with ventricular arrhythmias in a course of ischemic heart disease admitted to CCU. Clinical effects were evaluated in correlation with obtained lidocaine concentrations and basic pharmacokinetic parameters. Regression of cardiac arrhythmias was stated in 23 patients (79.3%), inclusive of all acute MI cases. Partial therapeutic effect was observed in 4 patients (13.8%) and no effect in 2 (6.9%). In 12 patients (52.2%) with stated regression of ventricular arrhythmias the full therapeutic effect was observed after initial dose administration. Serum drug concentrations were above the lower limit of the therapeutic range in all cases. Side effects were observed in 3 cases with high serum lidocaine levels caused by impaired drug metabolism or elimination due to the patient's clinical state. Correlation between the infusion rate and obtained stationary condition of drug concentration within therapeutic range seemed to be highly effective in management of ventricular premature beats caused by acute myocardial ischemia but less effective in cases of ischemic and postinfarction cardiomyopathy with heart failure.
Kardiol Pol 1989
PMID:[Therapeutic effectiveness of lidocaine in patients with ventricular arrhythmias estimated relative to measurements of drug concentration in serum]. 263 75

Hypertension is a well known risk factor of coronary artery disease. The aim of the study was to evaluate a clinical course and prognosis in hypertensive patients with acute myocardial infarction (MI). 100 consecutive patients with acute MI underwent the study. In 38 of them (28 males and 10 females) a history of hypertension and intermittent rises of arterial blood pressure in a course of MI were stated. All patients underwent 2-DE examination and 24 hours Holter ecg monitoring. Clinical characteristics consisted of the heart failure and arrhythmias occurrence as well as the in-hospital mortality. Significantly higher rate of MI in the past and/or angina pectoris as well as a diabetes mellitus was stated in hypertensive patients. In these patients inferior, transmural MI was more often observed, while there was no difference in life-threatening arrhythmias, pulmonary edema and cardiogenic shock between normotensive and hypertensive patients.
Kardiol Pol 1989
PMID:[Myocardial infarction in patients with hypertension]. 281 Oct 21

Craviten (M-71) increases the coronary flow, depresses the rate of contractions, and transiently depresses the contractile force of the cat heart in vitro and in situ. As the action of the drug is short-lasting, its usefulness in treatment of acute cardiac insufficiency accompanied by pain is suggested. It is also potentially useful in cardiac insufficiencies accompanied by arrhythmia.
Pol J Pharmacol Pharm
PMID:The influence of a new antiarrhythmic drug, Craviten (M-71) on coronary flow. 678 74


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>